Hyphens Pharma International - SAC Capital 2024-05-16: Robust Growth Across All Segments In 1Q24

Hyphens Pharma International - Robust Growth Across All Segments In 1Q24

Published:
Hyphens Pharma (SGX:1J5) | SGinvestors.ioHyphens Pharma (SGX:1J5)
  • Hyphens Pharma (SGX:1J5)'s revenue for 1Q24 has increased by 44.4% y-o-y to S$48.0m, driven by improvement in sales from all segments compared to a year ago which was heavily affected by supply chain disruptions.
  • - Read this at SGinvestors.io -

1Q24 results were within our expectations.

  • Correspondingly, gross profit improved by 32.8% y-o-y to S$17.4m. However, Hyphens Pharma's gross margin decreased to 36.3% in 1Q24 from 39.5% in 1Q23 due to ongoing cost pressures and a higher sales mix of lower margin products.
  • Net profit after tax surged by 97.6% y-o-y to S$2.7m, in line with the higher revenue. Consequently, gross profit fell 7.0% q-o-q and net profit decreased by 6.6% q-o-q.
  • - Read this at SGinvestors.io -

Optimism Intact



Advertisement

You May Also Like




SGX Stock / REIT Search

Advertisement

Most Read

Trust Bank God Of Fortune Referral Code PGKPSWAE Trust Bank Referral Code 🎁

Advertisement